EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise

Meryl Thomas iD, Madeline Hankins, Emadodin Darchini-Maragheh, Laita Bokhari, Samantha Eisman iD, Leona Yip iD, Katherine York iD, Jane Li, Pooja Sharma iD, Daranporn Triwongwaranat iD, Vijaya Chitreddy iD, Ragini Ghiya und 12 weitere

Australasian Journal of Dermatology · 2025-11 · 66 (7) · 404-412

DOI: 10.1111/ajd.14556 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Australasian Journal of Dermatology, online erschienen am 06.08.2025. Verfasst von Meryl Thomas und 23 weiteren Autor:innen. Beteiligte Einrichtung: Monash School of Medicine, Monash University, Melbourne, Australia. Hauptthemen laut MEDLINE: Alopecia Areata, Janus Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Australasian Hair and Wool Research Society.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives Janus kinase inhibitors (JAKis) have been approved by the Therapeutic Goods Administration for severe alopecia areata (AA) in Australia. However, access is limited as JAKis are not currently subsidised on the Pharmaceutical Benefits Scheme for this indication. This study aimed to establish expert consensus on criteria for initiating and continuing subsidised JAKi therapy for AA.

Methods

An eDelphi study was conducted with 26 Australian specialists in hair and scalp disorders, who participated in two online survey rounds. A third round, held as a virtual meeting, facilitated discussion. Consensus was defined as ≥ 75% agreement or disagreement.

Results

Twenty‐six, twenty‐two, and twenty‐five experts completed the first, second, and third rounds, respectively. Experts agreed that JAKis were nearly always the best treatment for cases with ≥ 50% scalp hair loss and usually the best treatment for 21%–49% scalp hair loss. The most important additional factors when assessing eligibility for JAKis were refractory disease, rapid progression, psychosocial morbidity, poorly camouflaged hair loss, ophiasis pattern, and impaired quality of life. Treatment failure was defined as < 50% improvement in scalp hair loss after 12 months of therapy. Indicators of remission included achieving SALT 0, regrowth of facial hair, improved DLQI scores, patient satisfaction, negative hair pull test, and reduced psychosocial impairment.

Conclusions

This expert consensus provides a framework for determining eligibility for subsidised JAKi therapy in Australian AA patients. Future research, supported by patient registries, should incorporate patient perspectives to further refine these criteria, ensure equitable access to treatment, and assess real‐world impact, safety, and effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataJanus Kinase InhibitorsHumansAustraliaConsensusQuality of Life

Substanzen

Janus Kinase Inhibitors

Autor:innen und Institutionen

  • Monash School of Medicine, Monash University, Melbourne, Australia.
  • Sinclair DIRECT, Dermatology Investigational Research, Education and Clinical Trials Centre, Melbourne, Australia.
  • Sinclair Dermatology, East Melbourne, Victoria, Australia.
  • Skin Partners, Specialist Dermatologists, Brisbane, Queensland, Australia.
  • Beachside Specialist Group, Noosa Heads, Queensland, Australia.
  • Skin Health Institute, Melbourne, Victoria, Australia.

ORCID-Profile: Meryl Thomas, Samantha Eisman, Leona Yip, Katherine York, Pooja Sharma, Daranporn Triwongwaranat, Vijaya Chitreddy, Daniella Kushnir-Grinbaum, John Frewen, Shin Shen Yong, William Cranwell, Dmitri Wall, Kiarash Khosrotehrani, Anthony Moussa, Rodney Sinclair

Förderung

  • Australasian Hair and Wool Research Society

Zitieren

APA

Thomas, M., Hankins, M., Darchini-Maragheh, E., Bokhari, L., Eisman, S., Yip, L., York, K., Li, J., Sharma, P., Triwongwaranat, D., Chitreddy, V., Ghiya, R., Kushnir-Grinbaum, D., Frewen, J., Yong, S. S., Rathnayake, D., Cranwell, W., Wall, D., Varathan, V., …, & Sinclair, R. (2025). Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise. Australasian Journal of Dermatology, 66(7), 404-412. https://doi.org/10.1111/ajd.14556

Vancouver

Thomas M, Hankins M, Darchini-Maragheh E, Bokhari L, Eisman S, Yip L, et al. Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise. Australasian Journal of Dermatology. 2025;66(7):404-412. doi:10.1111/ajd.14556

BibTeX
@article{Thomas2025,
  author = {Thomas, Meryl and Hankins, Madeline and Darchini-Maragheh, Emadodin and Bokhari, Laita and Eisman, Samantha and Yip, Leona and York, Katherine and Li, Jane and Sharma, Pooja and Triwongwaranat, Daranporn and Chitreddy, Vijaya and Ghiya, Ragini and Kushnir-Grinbaum, Daniella and Frewen, John and Yong, Shin Shen and Rathnayake, Deepani and Cranwell, William and Wall, Dmitri and Varathan, Vanathy and Khosrotehrani, Kiarash and Orchard, David and Moussa, Anthony and Paranjape, Meghana and Sinclair, Rodney},
  title = {Criteria for Commencing and Continuing Subsidised Janus Kinase Inhibitor Therapy in Australian Alopecia Areata Patients—Results From an Australian Expert Consensus Exercise},
  journal = {Australasian Journal of Dermatology},
  year = {2025},
  volume = {66},
  number = {7},
  pages = {404--412},
  doi = {10.1111/ajd.14556}
}
Kostenlos starten →